- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02314780
The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart
Pilot Trial: The Effects of Intravenous Heme Arginate on HO-1 Expression and Oxidative Stress in the Human Heart
Ischemia reperfusion injury may be attenuated by HO-1 induction. Our previous data confirmed strong HO-1 induction in peripheral blood cells following heme arginate infusion in healthy humans. Furthermore, we could demonstrate the amelioration of experimental ischemia reperfusion injury in the calf musculature by heme arginate in healthy subjects as measured by functional MRI.
Therefore, we propose that HO-1 induction in the human heart may be a suitable target to mitigate cardiac ischemia-reperfusion injury.
The HO-1 induction will be assessed in a clinical trial by myocardial biopsy prior to and after aortic cross-clamping in subjects with or without preceding heme arginate treatment in two different dosages. The HO-1 expression will also be measured in the clinical trials in peripheral blood mononuclear cells. As additional outcome, levels of myoglobin, creatine-kinase and troponin T and reactive oxygen species will be measured in plasma according to standard laboratory procedures.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Signed informed consent
- Men and women aged between 40 and 85 years (inclusive)
- Body mass index < 35 kg/m2
- Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study
Exclusion criteria (any of the following):
- Known hypersensitivity to the study drug or any excipients of the drug formulation
- Treatment with another investigational drug within 3 weeks prior to screening
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
- Severe renal failure (glomerula filtration rate < 30 ml/min)
- Moderately or severe impaired left ventricular function (ejection fraction < 40%)
- Moderately or severe impaired right ventricular function
- Systolic pulmonary pressure > 45 mmHg
- Acute or recent (<7 days) myocardial infarction
- Child bearing potential
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Heme arginate (high dose)
24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
|
Other Names:
|
Experimental: Heme arginate (low dose)
24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
|
Other Names:
|
Placebo Comparator: Placebo
24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heme Oxygenase-1 (HO-1) Messenger Ribonucleic Acid (mRNA) Levels (Atrial Tissue)
Time Frame: intraoperative
|
The right atrial appendage was clamped and cut for cannulation before cardiopulmonary bypass.
The tissue samples were snap-frozen in the operating theater after sampling.
|
intraoperative
|
Myocardial HO-1 mRNA Levels (Ventricular Tissue Before Aortic Cross-clamping)
Time Frame: intraoperative
|
A small biopsy was taken from the right ventricular free wall directly before aortic cross-clamping.
The tissue samples were snap-frozen in the operating theater after sampling.
|
intraoperative
|
Myocardial HO-1 mRNA Levels (Ventricular Tissue After Aortic Cross-clamping)
Time Frame: intraoperative
|
A small biopsy was taken from the right ventricular free wall after aortic clamp release before weaning from cardiopulmonary bypass.
The tissue samples were snap-frozen in the operating theater after sampling.
|
intraoperative
|
Myocardial HO-1 Protein Concentrations (Atrial Tissue)
Time Frame: intraoperative
|
The right atrial appendage was clamped and cut for cannulation before cardiopulmonary bypass.The tissue samples were snap-frozen.
Western blot analysis was performed.
The amount of HO-1 protein (quantified as pixels under the curve) was evaluated.
|
intraoperative
|
Myocardial HO-1 Protein Concentrations (Ventricular Tissue Before Aortic Cross-clamping)
Time Frame: intraoperative
|
A small biopsy was taken from the right ventricular free wall directly before aortic cross-clamping.
The tissue samples were snap-frozen.
Western blot analysis was performed.
The amount of HO-1 protein (quantified as pixels under the curve) was evaluated.
|
intraoperative
|
Myocardial HO-1 Protein Concentrations (Ventricular Tissue After Aortic Cross-clamping)
Time Frame: intraoperative
|
A small biopsy was taken from the right ventricular free wall after aortic clamp release before weaning from cardiopulmonary bypass.
The tissue samples were snap-frozen in the operating theater after sampling.
Western blot analysis was performed.
The amount of HO-1 protein (quantified as pixels under the curve) was evaluated.
|
intraoperative
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alfred Kocher, M.D., Medical University of Vienna
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HO-1 in the Heart
- 2013-000887-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
Foundation IRCCS San Matteo HospitalFondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaboratorsWithdrawnST-elevation Myocardial InfarctionItaly
-
INTEGRIS Baptist Medical CenterCompletedST Elevated Myocardial InfarctionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States